Nowadays, within a market where thousands of products coexist, the name of a drug has to be memorable. This article draws a typology of the main morphosemantic processes that are used in creating neologisms for brand-name drugs over three centuries. This analysis demonstrates that the pharmaceutical industry contravenes the rules established by the Food and Drug Administration (FDA) in proposing names with a high symbolic evocation.
